Long‐term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only

Arthritis & Rheumatism

Volumn 34, Issue 8, 1991, Pages 945-950

  Steinberg, Alfred D ^a   Steinberg, Susan C ^a  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; PREDNISONE;

ADULT; ARTICLE; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; KIDNEY FUNCTION; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AZATHIOPRINE; COMPARATIVE STUDY; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HUMAN; INJECTIONS, INTRAVENOUS; KIDNEY; KIDNEY FAILURE, CHRONIC; LUPUS NEPHRITIS; MIDDLE AGE; PREDNISONE; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 0025786860     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.1780340803     Document Type: Article

References (25)

1. Cyclophosphamide in lupus nephritis: a controlled trial
2. Azathioprine in the treatment of systemic lupus erythematosus: a controlled study
3. Treatment of lupus nephritis with prednisone and combine prednisone and azathioprine
4. Comparison of azathioprine, prednisone, and heparin alone or combined in treating lupus nephritis
5. Further observations on the treatment of lupus nephritis with prednisone and combined prednisone and azathioprine
6. Azathioprine plus prednisone compared with prednisone alone in the treatment of systemic lupus erythematosus: report of a prospective controlled trial in 24 patients
7. Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide
8. Cytotoxic drugs in treatment on non‐malignant diseases
9. Therapeutic studies in NZB/W mice. III. Relationship between renal status and efficacy of immunosuppressive drug therapy
10. A double‐blind controlled trial comparing cyclophosphamide, azathioprine and placebo in the treatment of lupus glomerulonephritis
11. Cyclophosphamide or azathioprine in lupus glomerulonephritis: a controlled trial: results at 28 months
12. Alternative modes of cyclophosphamide and azathioprine therapy in lupus nephritis
13. Controlled studies of oral immunosuppressive drugs in lupus nephritis: a long‐term follow‐up
14. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs
15. Preliminary criteria for the classification of systemic lupus erythematosus
16. Nonparametric estimation from incomplete observations
17. Evaluation of survival data and two new rank order statistics arising in its consideration
18. Prognostic factors in lupus nephritis: contribution of renal histologic data
19. Cyclophosphamide treatment of systemic lupus erythematosus: risk of bladder cancer exceeds benefit
20. Acute nonlymphocytic leukemia following short‐term, intermittent, intravenous cyclophosphamide treatment of lupus nephritis
21. Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis: results of a pooled analysis
22. Beneficial effects of methylprednisolone “pulse” therapy in diffuse proliferative lupus nephritis
23. Treatment of lupus nephritis with total lymphoid irradiation: observations during a 12–79‐month followup
24. Outcome of the acute glomerular injury in proliferative lupus nephritis